Molecular imaging with PET is a rapidly emerging technique. In breast cancer patients, more than 45 different PET tracers have been or are presently being tested. With a good rationale, after development of the tracer and proven feasibility, it is of interest to evaluate whether there is a potential meaningful role for the tracer in the clinical setting-such as in staging, in the (early) prediction of a treatment response, or in supporting drug choices. So far, only 18 F-FDG PET has been incorporated into breast cancer guidelines. For proof of the clinical relevance of tracers, especially for analysis in a multicenter setting, standardization of the technology and access to the novel PET tracer are required. However, resources for PET implementation research are limited. Therefore, next to randomized studies, novel approaches are required for proving the clinical value of PET tracers with the smallest possible number of patients. The aim of this review is to describe the process of the development of PET tracers and the level of evidence needed for the use of these tracers in breast cancer. Several breast cancer trials have been performed with the PET tracers 18 F-FDG, 3′-deoxy-3′-18 F-fluorothymidine ( 18 F-FLT), and 18 F-fluoroestradiol ( 18 F-FES). We studied them to learn lessons for the implementation of novel tracers. After defining the gap between a good rationale for a tracer and implementation in the clinical setting, we propose solutions to fill the gap to try to bring more PET tracers to daily clinical practice. Mol ecular imaging with PET is a rapidly emerging approach in oncology. This approach offers the potential to noninvasively determine tumor staging, make tumor response measurements, and characterize relevant drug targets in the tumor. Moreover, the wholebody 3-dimensional image provides information about all tumor lesions within a patient. This information is increasingly of potential interest because of progressive awareness of the existence of tumor heterogeneity for several clinical relevant characteristics (1,2). Interestingly, the development of tracers for most hallmarks of cancer allows the imaging of key characteristics of tumors in the research setting (3). More than 30 different PET tracers have been analyzed for their contributions to staging or early response measurements in breast cancer (Table 1 ). In addition, in the past 5 y, information on 15 different breast cancer tracers has been published. Many more are expected. However, at present, only the visualization of glucose uptake with 18 F-FDG PET is part of standard care and has been incorporated into breast cancer guidelines (4,5). New initiatives are attempting to bridge the gap between new chemical entities and clinical-grade radiopharmaceuticals, which then must be brought to the clinical setting. This process requires proof-of-concept feasibility studies; when sufficient evidence has accumulated, the tracer should be implemented in the clinical setting.
Mol ecular imaging with PET is a rapidly emerging approach in oncology. This approach offers the potential to noninvasively determine tumor staging, make tumor response measurements, and characterize relevant drug targets in the tumor. Moreover, the wholebody 3-dimensional image provides information about all tumor lesions within a patient. This information is increasingly of potential interest because of progressive awareness of the existence of tumor heterogeneity for several clinical relevant characteristics (1, 2) . Interestingly, the development of tracers for most hallmarks of cancer allows the imaging of key characteristics of tumors in the research setting (3) . More than 30 different PET tracers have been analyzed for their contributions to staging or early response measurements in breast cancer (Table 1 ). In addition, in the past 5 y, information on 15 different breast cancer tracers has been published. Many more are expected. However, at present, only the visualization of glucose uptake with 18 F-FDG PET is part of standard care and has been incorporated into breast cancer guidelines (4, 5) . New initiatives are attempting to bridge the gap between new chemical entities and clinical-grade radiopharmaceuticals, which then must be brought to the clinical setting. This process requires proof-of-concept feasibility studies; when sufficient evidence has accumulated, the tracer should be implemented in the clinical setting.
The aims of this review are to summarize the steps from preclinical to first-in-human studies and to summarize the current research on PET tracers and level of evidence (LoE) (6) concerning their contributions to the breast cancer field. We summarize the literature on 18 F-FDG, 39-deoxy-39-18 F-fluorothymidine ( 18 F-FLT), and 18 F-fluoroestradiol ( 18 F-FES) PET studies because several breast cancer trials have been performed. Our goal is to learn lessons about the potential steps for implementing more PET tracers in clinical practice.
SEARCH STRATEGY
To gain insight into novel PET tracers being tested in breast cancer, PubMed/Medline was searched, with special attention to studies involving 18 F-FDG, 18 F-FLT, and 18 F-FES tracers. In April 2015, ClinicalTrials.gov was searched for ongoing clinical trials with the search terms [PET] AND [breast cancer]. In total, 164 ongoing PET studies were found.
TRANSITION OF TRACERS FROM PRECLINICAL EVALUATION TO FIRST-IN-HUMAN STUDIES
Bringing tracers from the research-and-development phase to the clinical setting can be a major challenge. Several barriers can cause inefficient translation of novel chemical entities to clinicalgrade radiopharmaceuticals; these include lack of good-manufacturingpractice facilities, lack of resources, and insufficient knowledge of the translational process and regulatory requirements.
An investigational radiopharmaceutical for use in a clinical trial is an investigational medicinal product for which an investigational medicinal product dossier (IMPD) is required in Europe. In the United States, the procedure is similar; an investigational new drug application is submitted instead of an IMPD. The application includes data on product quality and safety. The IMPD is submitted together with the clinical trial application to the competent authority. The IMPD outlines the quality and safety of the investigational radiopharmaceutical based on data gathered during the development process.
In the first phase, on the basis of a good rationale, the radiochemical synthesis-including purification, characterization, initial formulation, and stability-is developed. The result of this phase is a development report, which describes the critical process steps and forms the basis for the subsequent technology transfer step. If tracer development is successful and preclinical data are not yet ENT1/TK1 5 equilibrative nucleoside transporter 1/thymidine kinase 1; ChK-α 5 choline kinase-α; Sig-2R 5 σ-receptor subtype 2; AR 5 androgen receptor; Α v β 3 5 vitronectin receptor integrin α-V and integrin β-3; 18 F-FMAU
,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid; EGFR 5 endothelial growth factor receptor; VEGF-A 5 vascular endothelial growth factor A; ABY-025 5 maleimide-DOTA-Cys61-ZHER2; CEA 5 carcinoembryonic antigen; NOTA-NFB 5 p-SCN-Bn-NOTA with T140-NFB; CXCR4 5 chemokine (C-X-C motif) receptor 4; AE105 5 urokinase plasminogen activator receptor antagonist; GLUT-1/HKII 5 glucose transporter 1/hexokinase 2; ONT-10 5 oncothyreon vaccin 10; MUC1 5 mucin 1.
available in the literature, the tracer is evaluated with in vitro and in vivo models to assess its biodistribution and estimate radiation dosimetry. Information from this preclinical evaluation phase is incorporated into the nonclinical pharmacology, pharmacokinetics, and toxicology section and the risk/benefit section of the IMPD. After a decision is made to translate the tracer to the clinical setting, the pharmaceutical or chemistry, manufacturing, and control phase starts. Techniques are transferred from the researchand-development laboratory setting to the good-manufacturingpractice environment. The manufacturing process is described, starting materials are defined, master batch records and testing procedures are documented, and final release specifications and inprocess controls are determined and their justification is described. Next, the analytic methods and the manufacturing process are validated, and the subsequent stability of the final drug product is assessed. The results of the pharmaceutical phase are approved master batch and testing records and validation and stability reports. This information is included in the chemical and pharmaceutical section of the IMPD.
If necessary, a toxicology study is performed, and the results are described in the nonclinical pharmacology, pharmacokinetics, and toxicology section. In the last step, all data are reviewed, and the final IMPD is authorized and submitted to the competent authority. A yearly product quality review and an update of the IMPD are mandatory.
Apart from product and process requirements, other essential elements that ensure final product quality are premises and equipment (qualified and monitored clean rooms, laminar flow hoods, and isolator hot cells); well-trained and qualified personnel; and a good-manufacturing-practice-quality system, including documentation and proper deviation and change in management.
The next step is a first-in-human trial, a small pilot study, for proof of concept and safety. When a tracer is proven safe and considered to be of clinical utility, larger studies with quality controls and standardization steps are required to gain the LoE needed to implement the tracer into the clinical setting. Most of the knowledge about the application of tracers in breast cancer trials concerns 18 F-FDG, 18 F-FLT, and 18 F-FES.
ROLE OF 18 F-FDG PET IN STANDARD BREAST CANCER CARE
Screening and Diagnosis 18 F-FDG PET scans are not part of current breast cancer screening, given that the lack of spatial resolution and low specificity result in false-positive scans. Better resolution is achievable with positron emission mammography (7), which was approved as a medical device by the U.S. Food and Drug Administration in 2003. It was introduced as a diagnostic adjunct to mammography and breast ultrasound but is still considered investigational, according to Blue Cross Blue Shield Association policy (8) . A metaanalysis of 8 studies comprising 873 women with suspected breast cancer showed a pooled sensitivity of 85% (95% confidence interval, 83%-88%) and a specificity per lesion of 79% (95% confidence interval, 74%-83%) (9) (LoE: 2). In addition, there are 6 ongoing positron emission mammography trials.
Staging
Besides standard imaging modalities, there is a possible role for 18 F-FDG PET in initial staging. National Comprehensive Cancer Network guidelines (4) specify no role for 18 F-FDG PET in the early stage (I or II) (10) (11) (12) (13) (14) ; European Society for Medical Oncology guidelines (5) suggest the use of 18 F-FDG PET/CT in early breast cancer when conventional imaging results are inconclusive. There is limited proof (LoE: 3) that 18 F-FDG PET/CT is helpful for identifying unsuspected regional nodal disease or distant metastases in stage III breast cancer when used in addition to standard staging studies (12, 13, (15) (16) (17) (18) (19) . Choosing Wisely recommends refraining from PET scanning during the staging of early breast cancer in individuals at low risk for metastases and in asymptomatic individuals who have been treated for breast cancer with curative intent (20) . 18 F-FDG PET is not recommended for diagnosing inflammatory breast cancer (5,21) because 18 F-FDG uptake caused by inflammatory processes decreases tumor specificity (22) . However, limited data suggest a possible role of 18 F-FDG PET for initial staging (23) (24) (25) and predicting survival (26) (LoE: 3).
Guideline recommendations for the use of 18 F-FDG PET/CT in patients with inoperable breast cancer or metastatic breast cancer (MBC) differ slightly. National Comprehensive Cancer Network guidelines state that the use of 18 F-FDG PET or PET/CT scanning is optional, is indicated only for inoperable advanced breast cancer or MBC, and is most helpful when the results of standard imaging studies are equivocal or suspect. Limited evidence supports the use of 18 F-FDG PET to evaluate the extent of disease in selected patients with recurrent or metastatic disease (11, 12, 27, 28) (LoE: 3). When 18 F-FDG PET/CT clearly shows bone metastases, no bone scan is needed, because of the high concordance between the modalities for bone metastases (29) . European Society for Medical Oncology 2014 guidelines (30) state that 18 F-FDG PET/CT can be used instead of CT and bone scanning for inoperable, locally advanced, noninflammatory breast cancer (31) (LoE: 2). Perhaps additional data in future trials can help to better define the indications. Current guidelines do not distinguish between differentiated and undifferentiated tumors. A retrospective analysis showed that hormone receptor-negative tumors had higher SUVs on 18 F-FDG PET than estrogen receptor (ER)-positive tumors and that uptake in lobular breast cancer was lower than that in ductal breast cancer, leading to false-negative results (32) .
Treatment response in trials is often evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1; these criteria are largely obtained by anatomic measurements (33) and are based on a collection of data from more than 6,500 trial patients with more than 18,000 target lesions treated in chemotherapy trials. 18 F-FDG PET has a role in progressive disease. Besides progressive disease indicated by progression on, for example, a CT scan, progressive disease is also defined as the occurrence of new lesions with positive 18 F-FDG PET scan results relative to the results of baseline 18 F-FDG PET scans. According to RECIST 1.1, bone metastases are evaluable only if at least 10 mm of soft tissue is involved. This information implies that MBC patients, more than 65% of whom develop bone metastases, often cannot be evaluated according to RECIST. Whether repeated 18 F-FDG PET/CT scans may play a role has yet to be determined.
Measurement of a response earlier than with current anatomic measurements (typically ;8-12 wk) is of interest because it can reduce the time of ineffective treatment, side effects, and unnecessary costs. In 77 MBC patients receiving neoadjuvant treatment, the metabolic response on 18 F-FDG PET/CT after 2 and 6 wk was related to an increased likelihood of a pathologic complete response (34) . However, the results were not correlated with overall survival, and multicenter standardization of 18 F-FDG PET techniques at baseline was not performed.
Fifteen ongoing breast cancer trials expected to accrue more than 1,200 patients are listed at ClinicalTrials.gov; these trials include repeated 18 Imaging of cellular proliferation with 18 F-FLT once held great promise for tumor imaging and quantifying a treatment response. However, the facts that the signal intensity is not always high enough and that false-negative and false-positive findings occur result in low sensitivity and specificity in breast cancer (35) . On the basis of 11 studies with 189 patients, 18 F-FLT PET is not a strong tool for staging or diagnosing breast cancer because of false-negative results for small axillary lymph nodes. It may play a role in predicting a therapy response. However, the results are equivocal (Table 2) . Moreover, it is difficult to pool individual patient data given the different outcome measurements and different imaging methods, labeling procedures, and scan protocols used.
F-FES PET IN BREAST CANCER
Therapy selection for breast cancer patients is mainly based on the presence of the ER, the progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Immunohistochemical (IHC) tumor staining for these receptors is considered to be the gold standard (4, 30) . In the MBC setting, repeated biopsies are advised because receptor expression can change over time. However, a biopsy does not necessarily capture inter-and intratumoral heterogeneity (36, 37) .
More than 70% of breast cancers overexpress the ER. This fact explains the major interest in the 16 18 F-FES PET studies performed in over 750 breast cancer patients (Table 3) . Six studies investigated the correlation between ER immunohistochemistry and 18 F-FES uptake; the correlation in all of them was good. Predicting the response to endocrine therapy was examined in 8 trials comprising 240 patients. Absence of 18 F-FES uptake predicted the failure of endocrine therapy (38, 39) , and a decrease in uptake during therapy indicated a response to the antihormonal drugs tamoxifen and fulvestrant (40) (41) (42) (43) .
The results of 11 new studies including an additional 852 patients are expected over the next few years (Table 4) . Pooling individual patient data may provide more solid evidence for the role of 18 F-FES PET in the clinical setting. However, pooling of data may be challenging given the various tracer dosages, time frames, and reconstructions used.
ER-positive and progesterone receptor-positive tumors showed less uptake of 18 F-FDG than hormone receptor-negative tumors (32) . The role of 18 F-FES PET imaging in staging has not yet been proven, but with the knowledge that 18 F-FDG PET often shows lower uptake in hormone-positive tumors, it can be hypothesized that 18 F-FES PET may be of help in staging for patients with such tumors. A trial comparing immunohistochemically determined hormonal status with 18 F-FES uptake in MBC patients with hormone receptor-positive or -negative disease before treatment is ongoing (NCT01957332) (44) .
MULTICENTER STUDIES AND REPRODUCIBILITY OF RESULTS
When multicenter studies are started, for all steps in the manufacturing process that are conducted at more than one center, evidence that the final drug products and manufacturing processes are comparable should be provided. This goal could be achieved by cross-validation of the manufacturing processes, including quality control. The National Cancer Institute Cancer Imaging Program has been creating investigational new drugs for use as imaging agents. A subset of the documents filed is being made available to the research community to implement the routine synthesis of tracers at various facilities and to assist investigators with the filing of their own investigational new drugs (45) .
A prerequisite for a relevant scan or biomarker for the clinical setting is a high degree of test-retest accordance; in addition, the results of the test should be independent of the hospital at which the test is performed. European Association of Nuclear Medicine procedure guidelines have set rules for harmonizing data and obtaining better reproducibility. The American College of Radiology and the European Association of Nuclear Medicine Research Ltd. accreditation programs, the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network, and the Quantitative Imaging Biomarkers Alliance of the Radiologic Society of North America are all initiatives to make (molecular) imaging a standardized diagnostic modality in clinical medicine and research. Fortunately, interest in and intention to combine European and U.S. guidelines for molecular imaging to gain more uniform data are growing (46) . A retrospective assessment of the compliance of 11 sites with an imaging guideline for 18 F-FDG PET, however, showed poor compliance, possibly affecting tumor uptake quantification (47) . These data show the need for prospective quality control during studies.
A protocol to guide the upfront performance of 18 F-FDG PET/ CT studies within the context of single-and multiple-center clinical trials has been published (48) . It provides standards for all phases of imaging in oncological trials. This Uniform Protocol for Imaging in Clinical Trials is another step toward the larger patient datasets and uniform databases that allow individual patient data meta-analysis. In analogy to the database formed for RECIST, data from different trials can be combined, providing the large patient groups required for solid evidence. Although current guidelines and accreditation programs focus on 18 F-FDG PET, similar approaches can be used for the new tracers.
TRIAL DESIGNS TO PROVE ROLES OF NEW MOLECULAR IMAGING METHODS IN CLINICAL SETTINGS
Implementing PET imaging as part of standard care requires proven safety and added benefit beyond existing care. Benefits can include improved patient outcomes as well as reduced costs or physical or emotional burdens on patients. Cost savings could be realized by avoiding surgeries and reducing exposure to ineffective treatments (49) .
Implementing PET scanning as a biomarker requires the procedure to score well on criteria such as the REMARK criteria (REporting recommendations for tumor MARKer prognostic studies) (50) . These criteria were drafted to guide researchers in reporting their studies for tumor markers in oncology, after it was acknowledged that only a few markers had been adopted into clinical practice. Randomized trials are advised to provide the best LoE in support of a screening or predictive biomarker (50) or to show the actual improved patient outcome of a new diagnostic or prognostic strategy incorporating PET imaging relative to routine care. Unfortunately, standard randomized trials are rarely achievable in the field of predictive markers and molecular imaging because of financial boundaries and the limited capacity of tracer production facilities.
Given these constraints, various approaches to prove the clinical value of PET tracers have been undertaken and can be postulated. In the United States, the National Oncologic PET Registry provided prospective data on the clinical impact in daily practice of over 250,000 18 F-FDG PET scans (51) . It has paved the path to defining relevant indications and reimbursement for 18 F-FDG PET. An international registry prospectively collecting data might be able to prove the role of 18 F-FES PET, with a likely added benefit in cases of clinical dilemmas (52, 53) . Such observational data, when gathered with rigorous methodology, can provide solid evidence for diagnostic and prognostic purposes. With regard to PET tracers for therapy response prediction, observational data can also provide important initial evidence. MBC patients may be the prime target population for a study of therapy response prediction because of the importance of the timely identification of noneffective treatment leading to progressive disease. In addition, tracer uptake can be linked to response measurements at a metastasis level instead of at a per-patient level to lead to increased statistical efficiency and to allow smaller proof-of-concept studies.
Ideally, after the standardization of procedures, smaller prospective studies with meaningful direct clinical endpoints can be pooled in a database for individual patient data meta-analysis and further validation, enabling the data for each patient to contribute to an increasing evidence base for PET imaging applications. Next, when evidence is deemed sufficient for a new tracer to be implemented as part of standard care, a stepped wedge cluster randomized trial could provide final evidence of benefit while actually taking advantage of the logistical challenges of implementing novel PET technology (54) . In such a trial, hospitals are randomized over a certain period of time to the start of implementation, and at the end of this period, all hospitals will have implemented the PET technology. Patient outcome and cost-effectiveness data for the old strategy can then be compared with those for the new strategy in a randomized fashion. There may not be a clear "one-size-fits-all" approach to evaluating the benefit of molecular imaging (55) . A prospective, multicenter observational cohort study is taking place in The Netherlands. Its aim is to evaluate the clinical utility of 18 F-FES, 89 Zr-trastuzumab, and baseline and early 18 F-FDG PET scans in 200 MBC patients. Endpoints include the correlation between PET scans and (progression-free) survival, cost-effectiveness, and quality of life. Apart from PET scans, other biomarkers, such as circulating tumor cells and DNA as well as tumor DNA and tumor biopsies, are being analyzed (44) . These strategies will allow study of the roles of 18 F-FDG, 18 F-FES, and 89 Zr-trastuzumab PET in relation to those of other potential novel biomarkers and will provide information beyond that provided by the standard of care. Another trial will evaluate the clinical utility of 18 F-FES PET in 99 hormone-positive MBC patients and its possible role, relative to that of 18 F-FDG PET, in predicting a response to therapy (NCT02398773).
Cost-effectiveness can be assessed in comparison with standard options and costs per life-year saved. Data on the cost-effectiveness of 18 F-FDG PET in breast cancer patients are limited. Computer models can be used to conduct cost-effectiveness studies (56) . In silico simulation studies could help optimize future studies. Such studies assist with the use of the smallest number of patients and thus with generating the lowest costs to obtain a meaningful response prediction signature. Simulated data not only can provide more information concerning the number of patients needed but also can help define thresholds for outcomes as well as define the optimal statistical analysis approach. The first attempt to assess added benefit in terms of the cost-effectiveness of 18 F-FES PET was made by simulating the follow-up for 5 y of women with ER-positive MBC (57) . The total costs for the 18 F-FES PET/CT strategy were higher than those for the standard workup or 18 F-FDG PET/CT. Nonetheless, the total number of performed diagnostic tests was smaller for each of the PET/CT strategies than for the standard workup.
CONCLUSION
Important steps have been taken in the field of breast cancer, especially for 18 F-FDG PET, leading to its role in daily practice. For other potential interesting tracers in the field of breast cancer, the path to the clinical setting can be facilitated through multidisciplinary efforts. Information on tracer development and investigational new drugs can be shared. Moreover, when data collection and scanning procedures are harmonized, measurements are standardized, and all procedures are documented carefully, an incremental valuable database can be developed. Optimal documentation and standardization can be supported by a standardized scan and analysis report form. The analysis of such database data can provide guidance regarding the optimal application, show what kind of additional evidence is needed (such as early health technology assessment), prioritize studies to provide this evidence, and provide important support and sufficient LoE-ultimately focusing and expediting implementation studies. Once multiple PET tracers have been incorporated into standard breast cancer care, the use of a combination may even provide more complete insight in individuals. Scans will provide information about molecular characteristics and heterogeneity across lesions in the body. This process may contribute significantly to superior personalized treatment through several new potential treatment options for breast cancer.
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